rofecoxib has been researched along with Neoplasms in 20 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty patients with advanced solid tumors were enrolled in this phase II trial, 43 of whom had received at least one prior chemotherapy regimen." | 2.72 | Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. ( Cano, PO; Germond, CJ; Lopez, PG; Noble, JC; Whissell, M; Young, SD, 2006) |
| "Neoplastic fever is relatively common in cancer patients." | 2.71 | Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. ( Kathula, SK; Koduri, J; Polenakovik, H; Shah, K, 2003) |
| "Among the most widely prescribed drugs worldwide, non-steroidal anti-inflammatory drugs (NSAIDs) are effective for relieving pain, but they are also associated with a high incidence of gastrointestinal (GI) adverse events." | 2.41 | Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? ( Devière, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 16 (80.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Xie, L | 1 |
| Li, R | 1 |
| Zheng, B | 1 |
| Xie, Z | 1 |
| Fang, X | 1 |
| Dai, T | 1 |
| Wang, X | 2 |
| Li, L | 1 |
| Wang, L | 1 |
| Cuny, GD | 1 |
| Eriksen, J | 1 |
| Tu, D | 1 |
| Chen, Z | 1 |
| Chen, X | 1 |
| Hu, M | 1 |
| Pereira, SAP | 1 |
| Bobbink, FD | 1 |
| Dyson, PJ | 1 |
| Saraiva, MLMFS | 1 |
| Devière, J | 1 |
| Kathula, SK | 1 |
| Shah, K | 1 |
| Polenakovik, H | 1 |
| Koduri, J | 1 |
| Gehrmann, M | 1 |
| Brunner, M | 1 |
| Pfister, K | 1 |
| Reichle, A | 1 |
| Kremmer, E | 1 |
| Multhoff, G | 1 |
| Gately, S | 1 |
| Li, WW | 1 |
| Jayr, C | 2 |
| Vanchieri, C | 2 |
| Couzin, J | 1 |
| Kamen, B | 1 |
| Kieran, M | 1 |
| Senior, K | 1 |
| Rigas, B | 1 |
| Kashfi, K | 1 |
| Young, SD | 1 |
| Whissell, M | 1 |
| Noble, JC | 1 |
| Cano, PO | 1 |
| Lopez, PG | 1 |
| Germond, CJ | 1 |
| Grösch, S | 1 |
| Maier, TJ | 1 |
| Schiffmann, S | 1 |
| Geisslinger, G | 1 |
| Ziegler, J | 1 |
| Dicker, AP | 1 |
| Williams, TL | 1 |
| Grant, DS | 1 |
| Sharma, RA | 1 |
8 reviews available for rofecoxib and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Hu | 2002 |
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Celecoxib; Cell Movement; Cyclooxygenase | 2004 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
Cancer prevention: a new era beyond cyclooxygenase-2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2005 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; H | 2004 |
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anti-Inflammatory Agents, N | 2006 |
Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer.
Topics: Arachidonic Acid; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C | 2002 |
2 trials available for rofecoxib and Neoplasms
| Article | Year |
|---|---|
Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship | 2003 |
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2006 |
10 other studies available for rofecoxib and Neoplasms
| Article | Year |
|---|---|
One-Step Transformation from Rofecoxib to a COX-2 NIR Probe for Human Cancer Tissue/Organoid Targeted Bioimaging.
Topics: Animals; Biocompatible Materials; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; H | 2021 |
Automatic evaluation of cyclooxygenase 2 inhibition induced by metal-based anticancer compounds.
Topics: Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Lactones; Metals; Neop | 2021 |
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; | 2004 |
Vioxx withdrawal alarms cancer prevention researchers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyc | 2004 |
Clinical trials. Nail-biting time for trials of COX-2 drugs.
Topics: Alzheimer Disease; Anticarcinogenic Agents; Cardiovascular Diseases; Celecoxib; Controlled Clinical | 2004 |
Don't throw out the baby with the bathwater!
Topics: Advertising; Cardiovascular Diseases; Child; Child Welfare; Clinical Trials as Topic; Cyclooxygenase | 2005 |
COX-2 inhibitors: cancer prevention or cardiovascular risk?
Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2005 |
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Ce | 2005 |
Early trials probe COX-2 inhibitors' cancer-fighting potential.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1999 |
Targeting angiogenic processes by combination rofecoxib and ionizing radiation.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Cell Division; Cells, Cultured; Cyclooxygenase 2 | 2001 |